Novavax says COVID vaccine for U.S. to be manufactured by India’s Serum

By:

Updated: Jun 7, 2022, 20:21 GMT+00:00

(Reuters) - Novavax Inc said on Tuesday that its COVID-19 vaccine initially available in the United States, if authorized, will be manufactured by the Serum Institute of India.

(Reuters) – Novavax Inc said on Tuesday that its COVID-19 vaccine initially available in the United States, if authorized, will be manufactured by the Serum Institute of India.

“So all vaccines that are being distributed globally commercially are being made in a single facility by our partners (the Serum Institute in India) that includes the vaccines which are being deployed around the world as well as the ones that will be initially deployed in the U.S.,” said Chief Medical Officer Filip Dubovsky.

(Reporting by Manas Mishra in Bengaluru; Editing by Chris Reese)

About the Author

Reuterscontributor

Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV. Learn more about Thomson Reuters products: